Extracellular Vesicles‐Derived Hybrid Nanoplatforms for Amplified CD47 Blockade‐Based Cancer Immunotherapy

Abstract

Immunomodulation of tumor‐associated macrophages (TAMs) into tumor‐inhibiting M1‐like phenotype is a promising but challenging strategy. Cleverly, tumor cells overexpress CD47, a “don't eat me” signal that ligates with the signal regulatory protein alpha (SIRPα) on macrophages to escape phagocytosis. Thus, effective re‐education of TAMs into the “eat me” type and blocking the CD47‐SIRPα signaling play pivotal roles in tumor immunotherapy. Herein, it is reported that hybrid nanovesicles (hEL‐RS17) derived from extracellular vesicles of M1 macrophages and decorated with RS17 peptide, an antitumor peptide that specifically binds to CD47 on tumor cells and blocks CD47‐SIRP α signaling, can actively target tumor cells and remodel TAM phenotypes. Consequently, more M1‐like TAMs infiltrate into tumor tissue to phagocytize more tumor cells due to CD47 blockade. By further co‐encapsulating chemotherapeutic agent shikonin, photosensitizer IR820, and immunomodulator polymetformin in hEL‐RS17, an enhanced antitumor effect is obtained due to the combinational treatment modality and close synergy among each component. Upon laser irradiation, the designed SPI@hEL‐RS17 nanoparticles exert potent antitumor efficacy against both 4T1 breast tumor and B16F10 melanoma models, which not only suppresses primary tumor growth but also inhibits lung metastasis and prevents tumor recurrence, exhibiting great potential in boosting CD47 blockade‐based antitumor immunotherapy.